COVID 19 infected patients will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

COVID 19 infected patients will receive one dose daily of Aerosolized All trans retinoic acid in gradual doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled All trans retinoic acid therapy for 14 days

4 Placebo tablets twice daily by mouth for 2 weeks

COVID -19

The infected patients will receive Aerosolized 13 cis retinoic acid in gradual in one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

Aerosolized 13 cis retinoic acid

The infected patients will receive Aerosolized All trans retinoic acid in gradual one dose increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled all trans retinoic acid therapy for 14 days

Aerosolized All trans retinoic acid

Placebo is a pill or tablet that does not contain any study drug.

Placebo

Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines

Proportion of lung injury score decreased or increased after treatment

Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

To determine the immune correlates of viral clearance (Antibody Titres sufficient for viral clearance and neutralizing ) against future exposure to SARS-CoV-2

Number of CD4 HLA-DR+ and CD38+, CD8 lymphocytes

Kidney failure, hypersensitivity with cutaneous or hemodynamic manifestations, aseptic meningitis, hemolytic anemia, leuko-neutropenia, transfusion related acute lung injury (TRALI)

serum levels of IgG and IgM against COVID-19

ACE2 expression in patients with COVID-19 infection

Mahmoud Ramadan mohamed Elkazzaz

Principal Investigator

Kafrelsheikh University

Damietta University

Nasopharyngeal & oropharyngeal swabs will be taken from patients with COVID-19

Coronavirus Disease (COVID-19)

Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center

To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database

Strain Study: To Access the Egyptian COVID-19 Whole Genome (Dominant Strain) by Next Generation Sequencing (NGS) and Compare to the International Worldwide Database

Identify the dominant viral genome strain in Egyptians With COVID-19 infection using next generation sequencing (NGS)

Hesham Elghazaly,MD

Director of Faculty of Medicine Ain Shams University Research Institute

Ain Shams University

Dengue Hemorrhagic

Albumins

Fluid

RSAB Harapan Kita

Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever

Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage

Level of Syndecan-1 in the first 4 hours after fluid resuscitation

Level of Syndecan-1 in the first 12 hours after fluid resuscitation

Level of Syndecan-1 in the first 24 hours after fluid resuscitation

Hematocrit value in the first 4, 12, and 24 hours after fluid resuscitation

Platelet count in the first 4, 12, and 24 hours after fluid resuscitation

Level of serum albumin in the first 4, 12, and 24 hours after fluid resuscitation

Quantitative urinary protein level in the first 24 and 48 hours after fluid resuscitation

Serum lactate level in the first 12 and 24 hours after fluid resuscitation

Patients' length of hospital stay through study completion

Rika Bur

Indonesia University

A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)

A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)

A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)

A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)

Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days

Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days

Healthy

As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

PMZ-2010 (Centhaquin)

Jahangir Clinical Development Centre Pvt. Ltd.

A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PMZ-2010 (Centhaquin) in Healthy Male Volunteers

Measure blood pressure, heart rate, body temperature, ECG, laboratory parameters and clinical assessment.after single and multiple ascending doses of PMZ-2010.

Maximum concentration (Cmax), Time of maximum plasma concentration (Tmax), Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration (AUClast), Terminal elimination half-life (t½), Clearance (CL/F), Apparent volume of distribution during the terminal elimination phase (Vz/F) of PMZ-2010 in plasma after single ascending doses.

Change in systolic and diastolic blood pressure, pulse rate, heart rate, QTcF after single ascending dose and multiple ascending doses

dengue/albumin

Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid ) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines

To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database

Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever

A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers

Najkompletnejšia databáza liečivých bylín podporovaná vedou